hematologic neoplasms

Summary

Summary: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.

Top Publications

  1. ncbi Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project
    Milena Sant
    Department of Preventive and Predictive Medicine, Unit of Analytical Epidemiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Blood 116:3724-34. 2010
  2. ncbi Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States
    Hilmar Wisplinghoff
    Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, 50935 Cologne, Germany
    Clin Infect Dis 36:1103-10. 2003
  3. doi Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies
    Yong Chong
    Department of Blood and Marrow Transplantation, Hara Sanshin Hospital, 1 8, Taihaku cho Hakata ku, Fukuoka, 812 0033, Japan
    Int J Infect Dis 15:e277-81. 2011
  4. ncbi Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy
    Juliet N Barker
    Blood and Marrow Transplant Program, Division of Medical and Pediatric Oncology, University of Minnesota, Box 480, 420 Delaware St SE, Minneapolis, MN 55455, USA
    Blood 105:1343-7. 2005
  5. doi Flow cytometric immunophenotyping for hematologic neoplasms
    Fiona E Craig
    Division of Hematopathology, Department of Pathology, University of Pittsburgh School of Medicine, PA, USA
    Blood 111:3941-67. 2008
  6. doi Fertility considerations and preservation in haemato-oncology patients undergoing treatment
    Avi Leader
    Department of Medicine A, Meir Medical Centre, Kfar Saba, Israel
    Br J Haematol 153:291-308. 2011
  7. pmc Mortality from lymphohematopoietic malignancies and brain cancer among embalmers exposed to formaldehyde
    Michael Hauptmann
    Department of Bioinformatics and Statistics, Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Natl Cancer Inst 101:1696-708. 2009
  8. pmc Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries: the National Cancer Institute Cohort
    Laura E Beane Freeman
    Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    J Natl Cancer Inst 101:751-61. 2009
  9. ncbi Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications
    Margret S Rodrigues
    Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, and Harvard Medical School, Boston, Massachusetts 02115, USA
    Antioxid Redox Signal 10:1813-48. 2008
  10. doi Progress in the curative treatment of childhood hematologic malignancies
    Alan S Wayne
    J Natl Cancer Inst 100:1271-3. 2008

Detail Information

Publications358 found, 100 shown here

  1. ncbi Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project
    Milena Sant
    Department of Preventive and Predictive Medicine, Unit of Analytical Epidemiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Blood 116:3724-34. 2010
    ..Differences in diagnostic and registration criteria are an important cause of incidence variation; however, different distribution of HM risk factors also contributes. The quality of population-based HM data needs further improvement...
  2. ncbi Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States
    Hilmar Wisplinghoff
    Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, 50935 Cologne, Germany
    Clin Infect Dis 36:1103-10. 2003
    ..The source of BSI was not determined for 57% of patients. The crude mortality rate was 36% for neutropenic patients and 31% for nonneutropenic patients...
  3. doi Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies
    Yong Chong
    Department of Blood and Marrow Transplantation, Hara Sanshin Hospital, 1 8, Taihaku cho Hakata ku, Fukuoka, 812 0033, Japan
    Int J Infect Dis 15:e277-81. 2011
    ..This study assessed the effect of discontinuing quinolone prophylaxis on the etiology and the resistance pattern of blood culture isolates and on the prognosis among febrile neutropenic patients receiving chemotherapy...
  4. ncbi Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy
    Juliet N Barker
    Blood and Marrow Transplant Program, Division of Medical and Pediatric Oncology, University of Minnesota, Box 480, 420 Delaware St SE, Minneapolis, MN 55455, USA
    Blood 105:1343-7. 2005
    ..Therefore, transplantation of 2 partially HLA-matched UCB units is safe, and may overcome the cell-dose barrier that limits the use of UCB in many adults and adolescents...
  5. doi Flow cytometric immunophenotyping for hematologic neoplasms
    Fiona E Craig
    Division of Hematopathology, Department of Pathology, University of Pittsburgh School of Medicine, PA, USA
    Blood 111:3941-67. 2008
    ..remains an indispensable tool for the diagnosis, classification, staging, and monitoring of hematologic neoplasms. The last 10 years have seen advances in flow cytometry instrumentation and availability of an expanded ..
  6. doi Fertility considerations and preservation in haemato-oncology patients undergoing treatment
    Avi Leader
    Department of Medicine A, Meir Medical Centre, Kfar Saba, Israel
    Br J Haematol 153:291-308. 2011
    ..Pre-pubertal patients present a unique constellation of fertility considerations, especially as embryo and sperm cryopreservation are not applicable to this age group...
  7. pmc Mortality from lymphohematopoietic malignancies and brain cancer among embalmers exposed to formaldehyde
    Michael Hauptmann
    Department of Bioinformatics and Statistics, Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Natl Cancer Inst 101:1696-708. 2009
    ..We investigated the relation of mortality to work practices and formaldehyde exposure levels among these professionals to address cancer risk in the funeral industry...
  8. pmc Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries: the National Cancer Institute Cohort
    Laura E Beane Freeman
    Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    J Natl Cancer Inst 101:751-61. 2009
    ....
  9. ncbi Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications
    Margret S Rodrigues
    Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, and Harvard Medical School, Boston, Massachusetts 02115, USA
    Antioxid Redox Signal 10:1813-48. 2008
    ..The underlying mechanisms leading to elevated oxidative stress are reviewed, and signaling mechanisms that may serve as novel targeted approaches to overcome ROS-dependent cell growth are discussed...
  10. doi Progress in the curative treatment of childhood hematologic malignancies
    Alan S Wayne
    J Natl Cancer Inst 100:1271-3. 2008
  11. doi Epigenetic inactivation of the hsa-miR-203 in haematological malignancies
    Chor Sang Chim
    Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
    J Cell Mol Med 15:2760-7. 2011
    ..In NHL, hsa-miR-203 methylation was associated with concomitant methylation of other tumour suppressor miRNAs. The frequent hsa-miR-203 methylation in lymphoid malignancies suggested a pathogenetic role of hsa-miR-203 methylation...
  12. doi Polymorphisms in Toll-like receptor genes and susceptibility to infections in allogeneic stem cell transplantation
    Agostinho Carvalho
    Microbiology, Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Perugia, Italy
    Exp Hematol 37:1022-9. 2009
    ..Discovery of genetic variations in the genes encoding for Toll-like receptors (TLRs) has highlighted a potential link between genomic variation of the host and susceptibility to infections...
  13. pmc Risk of lymphatic or haematopoietic cancer mortality with occupational exposure to animals or the public
    M A Svec
    Department of Epidemiology, University of Washington, Seattle, Washington, USA
    Occup Environ Med 62:726-35. 2005
    ..Occupational exposure to animals or the public could result in exposure to infectious agents, which may play a role in the aetiology of lymphohaematopoietic (LH) cancers...
  14. doi Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia
    J Styczynski
    Department of Pediatric Hematology and Oncology, Collegium Medicum UMK, Bydgoszcz, Poland
    Bone Marrow Transplant 43:757-70. 2009
    ..The clinical and scientific background was described and discussed, and the quality of evidence and level of recommendation were graded according to the Centers for Disease Control criteria...
  15. doi The role of microRNAs in normal and malignant hematopoiesis
    Diamantina Vasilatou
    Second Department of Internal Medicine, University of Athens, University General Hospital Attikon, Haidari, Greece
    Eur J Haematol 84:1-16. 2010
    ..The purpose of this review is to summarize current knowledge on the role of microRNAs in normal hematopoiesis and hematopoietic malignancies and, moreover, to highlight their role as potential therapeutic tools...
  16. ncbi Epigenetic changes in solid and hematopoietic tumors
    Minoru Toyota
    Sapporo Medical University, Sapporo, Japan
    Semin Oncol 32:521-30. 2005
    ..Pharmacologic manipulation of these patterns-epigenetic therapy-is also poised to change the way we treat cancer in the clinic...
  17. pmc Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease
    Claudio G Brunstein
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis MN, USA
    Blood 110:3064-70. 2007
    ..01) and use of 2 UCB units (P = .07). These findings support the use of UCB after a nonmyeloablative conditioning as a strategy for extending the availability of transplantation therapy, particularly for older patients...
  18. pmc Epigenetic inactivation of the miR-124-1 in haematological malignancies
    Kwan Yeung Wong
    Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong
    PLoS ONE 6:e19027. 2011
    ..Amongst haematological cancers, miR-124-1 was more frequently hypermethylated in NHL, and hence warrants further study...
  19. doi Epidemiology of oral yeast colonization and infection in patients with hematological malignancies, head neck and solid tumors
    Silke Schelenz
    Department of Microbiology, Norfolk and Norwich University Hospital, Norwich, UK
    J Oral Pathol Med 40:83-9. 2011
    ..The aim of this study was to investigate the epidemiology of oral yeast colonization and infection amongst cancer patients...
  20. pmc Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
    William Kevin Kelly
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
    J Clin Oncol 23:3923-31. 2005
    ..To determine the safety, dosing schedules, pharmacokinetic profile, and biologic effect of orally administered histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with advanced cancer...
  21. ncbi Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction
    Steven M Devine
    The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
    Blood 112:990-8. 2008
    ..This trial was registered as no. NCT00241358 at www.ClinicalTrials.gov...
  22. doi Use of antibacterial prophylaxis for patients with neutropenia. Australian Consensus Guidelines 2011 Steering Committee
    M A Slavin
    Department of Infectious Diseases, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Intern Med J 41:102-9. 2011
    ..The group also provides recommendations for monitoring and surveillance of emerging resistance in those centres that have adopted FQ prophylaxis...
  23. ncbi The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit
    M Craig
    Department of Medicine, Mary Babb Randolph Cancer Center, West Virginia University Hospitals, Morgantown, WV 26506 9162, USA
    Bone Marrow Transplant 39:477-82. 2007
    ..gram-negative bacteremia was significantly decreased, without emergence of resistance. Concerns with Gram-positive resistance will require further observation...
  24. doi The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan
    Yi Ju Chen
    Taichung Veterans General Hospital, Taichung and National Yang Ming University, Taipei, Taiwan
    Arthritis Rheum 63:352-8. 2011
    ..The aim of this study was to investigate the relative risk of cancer in Taiwanese patients with RA and to identify groups of patients with a high risk of cancer...
  25. doi Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies
    Enrico M Trecarichi
    Institute of Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    J Infect 58:299-307. 2009
    ..Particular attention was focused on defining the impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance by the bacterial isolates on mortality...
  26. ncbi Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries
    Michael Hauptmann
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    J Natl Cancer Inst 95:1615-23. 2003
    ..We extended follow-up of a cohort of industrial workers to evaluate the association between formaldehyde exposure and lymphohematopoietic cancers...
  27. doi A prospective survey of febrile events in hematological malignancies
    L Pagano
    Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Largo Francesco Vito, 1, I 00168 Roma, Italy
    Ann Hematol 91:767-74. 2012
    ..The Hema e-Chart provided a complete system for the epidemiological study of infectious complications in HMs...
  28. ncbi A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation
    B Bolwell
    Department of Hematology and Medical Oncology, Department of Biostatistics and Epidemiology, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Bone Marrow Transplant 34:621-5. 2004
    ....
  29. doi Cefepime-resistant Gram-negative bacteremia in febrile neutropenic patients with hematological malignancies
    Yong Chong
    Department of Blood and Marrow Transplantation, Hara Sanshin Hospital, 1 8 Taihaku cho, Hakata Ku, Fukuoka, Japan
    Int J Infect Dis 14:e171-5. 2010
    ..This study was performed to determine the local etiologic pattern of blood culture isolates and antibiotic resistance in febrile neutropenic patients with hematological malignancies...
  30. ncbi Antibiotic cycling to decrease bacterial antibiotic resistance: a 5-year experience on a bone marrow transplant unit
    J Cadena
    Department of Medicine, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Bone Marrow Transplant 40:151-5. 2007
    ..30-0.63 and OR: 0.38, 95% CI: 0.26-0.56). Cycling was associated with preserved antibiotic susceptibility among Gram-negatives, but with an increase in Enterococcus spp. and vancomycin and ampicillin resistance among enterococci...
  31. doi Formaldehyde and lymphohematopoietic cancers: a review of two recent studies
    Philip Cole
    Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA
    Regul Toxicol Pharmacol 58:161-6. 2010
    ..Both studies included subjects with considerable exposure to formaldehyde and both are focused on the myeloid leukemias...
  32. ncbi Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation
    J Maertens
    Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium
    Blood 97:1604-10. 2001
    ..In conclusion, serial screening for GM, complemented by appropriate imaging techniques, is a sensitive and noninvasive tool for the early diagnosis of IA in high-risk adult hematology patients...
  33. ncbi 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia
    Brent L Wood
    Department of Laboratory Medicine, University of Washington Medical Center, Seattle, Washington 98195, USA
    Cytometry B Clin Cytom 72:S14-22. 2007
    ..The 2006 Bethesda Consensus conference represents the first successful attempt to define a set of consensus reagents suitable for the initial evaluation of hematopoietic neoplasia...
  34. pmc Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood
    Claudio G Brunstein
    University of Minnesota Medical Center, Minneapolis, MN, USA
    Blood 116:4693-9. 2010
    ..For patients without an available HLA matched donor, the use of 2 partially HLA-matched UCB units is a suitable alternative...
  35. doi Comparison of PCR-ELISA and Real-Time PCR for invasive aspergillosis diagnosis in patients with hematological malignancies
    Ines Hadrich
    Fungal and Parasitic Molecular Biology Laboratory, Sfax School of Medicine, Sfax, Tunisia
    Med Mycol 49:489-94. 2011
    ..Combining real-time PCR and GMA detection for both serum and BAL samples enhances routine laboratory IA diagnosis...
  36. pmc Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009
    Marie Christine Nicolle
    Service d Hygiène, Epidémiologie et Prévention, Groupement Hospitalier Edouard Herriot, Hospices Civils de Lyon, France
    Haematologica 96:1685-91. 2011
    ..The study objectives were: 1) to report on invasive aspergillosis patients in a hematology department; and 2) to estimate its incidence according to the hematologic diagnosis...
  37. doi Pharmacological activation of the p53 pathway in haematological malignancies
    Manujendra N Saha
    Division of Cellular and Molecular Biology, Toronto General Hospital Research Institute, University of Toronto, Canada
    J Clin Pathol 63:204-9. 2010
    ..This review will highlight recent findings in the research into molecules capable of modulating p53 protein activities and mechanisms that activate the p53 pathway, restoring response to therapy in haematological malignancies...
  38. ncbi 2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: medical indications
    B H Davis
    Trillium Diagnostics, Brewer, Maine, USA
    Cytometry B Clin Cytom 72:S5-13. 2007
    ..This report summarizes the appropriate use of diagnostic flow cytometry as determined by unanimous approval of these experienced practitioners...
  39. ncbi Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia
    C Y Chen
    Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan
    Epidemiol Infect 138:1044-51. 2010
    ..calcoaceticus-baumannii complex and vancomycin-resistant enterococci were also found during the study period. Emerging antimicrobial resistant pathogens are an increasing threat to neutropenic cancer patients...
  40. doi The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy
    Ray Hachem
    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 112:2493-9. 2008
    ..The objective of the current retrospective study was to compare the epidemiology of candidemia and its risk factors in patients who had hematologic malignancies(HM) with those in patients who had solid tumors (ST)...
  41. ncbi Formaldehyde and cancer risk: a quantitative review of cohort studies through 2006
    C Bosetti
    Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Ann Oncol 19:29-43. 2008
    ..Occupational exposure to formaldehyde has been associated with excess risk of nasopharyngeal and selected other cancers...
  42. ncbi Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy
    Karen K Ballen
    Cancer Center and Department of Medicine, University of Massachusetts Memorial Health Care, Worcester, MA, USA
    Blood 100:442-50. 2002
    ..Low-dose TBI and allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy...
  43. ncbi The fundamental role of epigenetics in hematopoietic malignancies
    Oliver Galm
    Medizinische Klinik IV, Universitaetsklinikum Aachen, 52074 Aachen, Germany
    Blood Rev 20:1-13. 2006
    ..The ongoing exploration of basic events involved in altered gene transcription patterns and continued clinical investigative studies are helping to develop novel strategies for the diagnosis, prevention, and treatment of human cancer...
  44. ncbi Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously
    Wm Kevin Kelly
    Genitourinary Oncology Service, Departments of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Cancer Res 9:3578-88. 2003
    ..To evaluate the safety, pharmacokinetics, and biological activity of suberoylanilide hydroxamic acid (SAHA) administered by 2-h i.v. infusion in patients with advanced cancer...
  45. ncbi Molecular cytogenetic aspects of hematological malignancies: clinical implications
    Zhong Chen
    Cytogenetics Laboratory, Room 1C210 SOM, Division of Medical Genetics, Department of Pediatrics, University of Utah School of Medicine, 50 North Medical Drive, Salt Lake City, UT 84132, USA
    Am J Med Genet 115:130-41. 2002
    ..With such information, the physician is in a more favorable position to devise therapy, appraise diagnosis, and plan follow-up...
  46. ncbi Prospective evaluation of gut mucosal barrier injury following various myeloablative regimens for haematopoietic stem cell transplant
    N M A Blijlevens
    Department of Haematology, University Medical Centre, St Radboud, Nijmegen, The Netherlands
    Bone Marrow Transplant 35:707-11. 2005
    ..These results confirm that the integrity and absorptive capacity of the gut is affected adversely by myeloablative regimens in general, although only two patterns of mucosal injury emerged depending on whether or not idarubicin was used...
  47. ncbi Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen
    P Frere
    Department of Medicine, Division of Haematology, University of Liege, Liege, Belgium
    Bone Marrow Transplant 37:411-8. 2006
    ..In conclusion, after NMSCT, infections are not frequent in the first 30 days post transplant but careful long-term monitoring is necessary thereafter...
  48. ncbi The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study
    Livio Pagano
    Istituto di Ematologi, Universita Cattolica del Sacro Cuore, Largo Francesco Vito, 1, I 00168 Rome, Italy
    Haematologica 91:1068-75. 2006
    ..The aim of this study was to evaluate the incidence and outcome of invasive fungal infections (IFI) in patients with hematologic malignancies...
  49. ncbi Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program
    Sergio Giralt
    The Nonmyeloablative Study Group, Center for International Blood and Marrow Transplant Research and the National Marrow Donor Program, Minneapolis, Minneapolis, USA
    Biol Blood Marrow Transplant 13:844-52. 2007
    ..However, only prospective trials will define the optimal role of this therapy in patients with hematologic malignancies. Therefore, URD transplantation with RIC should continue to be explored in the context of clinical trials...
  50. ncbi Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice
    Scott C Kogan
    Comprehensive Cancer Center and Department of Laboratory Medicine, University of California, San Francisco, 94143, USA
    Blood 100:238-45. 2002
    ..This classification will be of particular value to investigators seeking to develop, use, and communicate about mouse models of human hematopoietic neoplasms...
  51. ncbi Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program
    Chatchada Karanes
    City of Hope National Medical Center, Duarte, California, USA
    Biol Blood Marrow Transplant 14:8-15. 2008
    ..Correspondingly, survival within each disease category has improved. Particularly gratifying are the results in severe aplastic anemia (AA) where 2-year survival has doubled in just 10 years...
  52. pmc Admission factors associated with hospital mortality in patients with haematological malignancy admitted to UK adult, general critical care units: a secondary analysis of the ICNARC Case Mix Programme Database
    Peter A Hampshire
    Royal Liverpool University Hospital, Prescot Street, Liverpool, L7 8XP, UK
    Crit Care 13:R137. 2009
    ....
  53. pmc An in vivo model of double-unit cord blood transplantation that correlates with clinical engraftment
    Lamis K Eldjerou
    Allogeneic Bone Marrow Transplantation, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 116:3999-4006. 2010
    ..Thus, unit dominance is an in vivo phenomenon probably associated with a graft-versus-graft immune interaction mediated by CD34(-) cells...
  54. ncbi Invasive fungal infections in hematology: new trends
    R Martino
    Division of Clinical Hematology, Hospital de la Sant Creu i Sant Pau, Av Sant Antoni Ma Claret, 167, 08025 Barcelona, Spain
    Ann Hematol 81:233-43. 2002
    ..However, the exact place of these agents in treating different IFI will need to be found in the near future...
  55. doi Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis
    Georgios Chamilos
    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Infect Dis 47:503-9. 2008
    ..Zygomycosis is an emerging opportunistic mycosis among immunocompromised patients with a particularly poor prognosis...
  56. ncbi 2006 Bethesda International Consensus Conference on Flow Cytometric Immunophenotyping of Hematolymphoid Neoplasia
    Maryalice Stetler-Stevenson
    Laboratory of Pathology, NCI, NIH, Bethesda, Maryland 20892, USA
    Cytometry B Clin Cytom 72:S3. 2007
  57. ncbi Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients
    C Viscoli
    University of Genova and the National Institute for Cancer Research, Genoa, Italy
    Clin Microbiol Infect 12:212-6. 2006
    ..It was concluded that piperacillin-tazobactam could be considered as monotherapy for patients with high-risk febrile neutropenia...
  58. ncbi Influence of human leucocyte antigen disparity and graft lymphocytes on allogeneic engraftment and survival after umbilical cord blood transplant in adults
    Willem J van Heeckeren
    Department of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA
    Br J Haematol 139:464-74. 2007
    ....
  59. ncbi Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning
    J S Kalpoe
    Department of Medical Microbiology, Leiden University Medical Center, Albinudreef 2, 2300 RC Leiden, The Netherlands
    Bone Marrow Transplant 40:137-43. 2007
    ..RIC with fludarabine, ATG and busulphan demonstrated safety comparable to conventional MAC with regard to frequency and severity of CMV infections within 100 days following T cell-depleted allo-SCT...
  60. doi Delayed platelet recovery after allogeneic transplantation: a predictor of increased treatment-related mortality and poorer survival
    P Ramirez
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA
    Bone Marrow Transplant 46:981-6. 2011
    ..DPR is a significant independent risk factor for increased TRM and poorer OS along with HLA-mismatched URD, but not UCB, grade II-IV acute GVHD, old age and advanced disease stage...
  61. doi Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients
    M Scartozzi
    Department of Medical Oncology, United Hospitals, Polytechnic Marche University, Ancona, Italy
    Ann Oncol 22:897-902. 2011
    ..Preclinical studies suggested that integrins are relevant for gastric cancer diffusion. We investigated integrins polymorphisms role in determining peritoneal carcinosis or hematogenous metastases in radically resected gastric cancer...
  62. ncbi Cost-benefit assessment of antifungal prophylaxis with liposomal amphotericin B in neutropenic patients
    Olaf Penack
    Department of Hematology, Oncology, and Transfusion Medicine, Charite Campus Benjamin Franklin, Berlin, Germany
    Onkologie 30:621-6. 2007
    ..2 vs. 4.6%, p < 0.001) in high-risk patients with hematological malignancies and prolonged neutropenia...
  63. doi Disseminated intravascular coagulation in hematologic malignancies
    Massimo Franchini
    Department of Pathology and Laboratory Medicine, Immunohematology and Transfusion Center, University Hospital, Parma, Italy
    Semin Thromb Hemost 36:388-403. 2010
    ..Current approaches and open issues for the management and treatment of these patients are also reviewed...
  64. ncbi Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections
    Robin de Vries
    Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
    Pharmacoeconomics 26:75-90. 2008
    ..As the diagnosis of invasive fungal infections is difficult, effective antifungal prophylaxis is desirable. So far, fluconazole has been the most commonly used...
  65. ncbi Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors
    Renee M Y Barge
    Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
    Exp Hematol 31:865-72. 2003
    ..To reduce the incidence of GVHD, we treated a group of high-risk patients with a reduced-intensity conditioning regimen followed by in vitro T-cell-depleted alloSCT using Campath 1-H incubation...
  66. ncbi Interleukin-15 supports generation of highly potent clinical-grade natural killer cells in long-term cultures for targeting hematological malignancies
    Garnet Suck
    Blood Services Group, Health Sciences Authority, Singapore
    Exp Hematol 39:904-14. 2011
    ..Interleukin (IL)-15 is a promising novel cytokine for natural killer (NK) cell activation and survival. We studied the effects of IL-15 compared to IL-2 on NK cells in long-term cultures for clinical translation...
  67. ncbi Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality
    Arlo Upton
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA 98109, USA
    Clin Infect Dis 44:531-40. 2007
    ..The aim of this study was to determine the probability of survival and prognostic factors associated with outcomes over a long period of time...
  68. doi The impact of oral herpes simplex virus infection and candidiasis on chemotherapy-induced oral mucositis among patients with hematological malignancies
    Y K Chen
    Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
    Eur J Clin Microbiol Infect Dis 30:753-9. 2011
    ..001). Our results suggest that Candida albicans and HSV-1 play an important role in chemotherapy-induced OM in patients with hematological malignancies...
  69. pmc An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital
    L J Worth
    Victorian Infectious Diseases Service, Centre for Clinical Research Excellence in Infectious Diseases, Grattan Street, Parkville, Victoria 3050, Australia
    Br J Cancer 92:867-72. 2005
    ..Successful primary prevention of PCP in this population will require a multifaceted approach targeting the suboptimal prescribing patterns for chemoprophylaxis...
  70. ncbi FISH analysis of hematological neoplasias with 1p36 rearrangements allows the definition of a cluster of 2.5 Mb included in the minimal region deleted in 1p36 deletion syndrome
    Idoya Lahortiga
    Laboratory of Genetics, Division of Oncology, Center for Applied Medical Research CIMA, University of Navarra, Pio XII, 55, 31080, Pamplona, Spain
    Hum Genet 116:476-85. 2005
    ..5 Mb of the complete 1p36 band. This could explain its proneness for involvement in chromosomal rearrangements in hematological neoplasias...
  71. doi Granzymes A and B serum levels in allo-SCT
    B Kircher
    Department of Internal Medicine V Hematology and Oncology, Immunobiology and Stem Cell Laboratory, Innsbruck Medical University, Innsbruck, Austria
    Bone Marrow Transplant 43:787-91. 2009
    ..Similar effects were observed with GrB. In conclusion, Gr protein levels can also be used as a marker for complications after Allo-SCT...
  72. doi Sinus surgery combined with antifungal therapy is effective in the treatment of invasive Aspergillus sinusitis in neutropenic patients with cancer
    R Y Hachem
    Dept of Infectious Diseases, Infection Control and Employee Health, Unit 402, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Infection 36:539-42. 2008
    ..Invasive Aspergillus sinusitis (IAS) is associated with high mortality and poor response to antifungal therapy in patients with hematologic malignancies (HM)...
  73. pmc NKG2D gene polymorphism has a significant impact on transplant outcomes after HLA-fully-matched unrelated bone marrow transplantation for standard risk hematologic malignancies
    J Luis Espinoza
    Department of Hematology and Oncology, Kanazawa University Hospital, 13 1 Takaramachi, Kanazawa, 920 8641, Japan
    Haematologica 94:1427-34. 2009
    ....
  74. ncbi Neurologic complications of hematologic neoplasms
    Lawrence Recht
    Department of Neurology, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA
    Neurol Clin 21:87-105. 2003
    ..This article summarizes such complications that occur as a result of direct infiltration or compression of nervous tissue by tumor or as a result of indirect effects such as infection, vascular disorders, iatrogenesis, and paraneoplasia...
  75. ncbi Platelet alloimmunization in multitransfused patients with haemato-oncological disorders
    Meenu Bajpai
    Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India
    Natl Med J India 18:134-6. 2005
    ..We also assessed the effect of alloimmunization on response to platelet transfusion...
  76. ncbi Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections
    M J Vasconcelles
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 6:35-43. 2000
    ....
  77. ncbi Family history of hematopoietic malignancy and risk of lymphoma
    Ellen T Chang
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    J Natl Cancer Inst 97:1466-74. 2005
    ....
  78. ncbi Mitochondrial DNA in human malignancy
    J S Penta
    Office of Clinical Research, National Institute of Environmental Health Sciences, National Institutes of Health, P O Box 12233, MD A2 05, Research Triangle Park, NC 27709, USA
    Mutat Res 488:119-33. 2001
    ..Finally, we examine the role of reactive oxygen species (ROS) generated by mitochondria in the process of carcinogenesis...
  79. ncbi Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg
    Manel Esteller
    Cancer Epigenetics Laboratory, Spanish National Cancer Center CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Clin Immunol 109:80-8. 2003
    ..Furthermore, promising studies using DNA demethylating agents and histone deacetylase inhibitors are underway to awake these dormant tumor-suppressor genes for a better treatment of the patient with a hematologic malignancy...
  80. ncbi Tumor infiltration of bone marrow in patients with hemato-logical malignancies: dynamic contrast-enhanced magnetic resonance imaging
    Lei Zhang
    Department of Radiology, Tongji Hospital of Tongji University, Shanghai 200065, China
    Chin Med J (Engl) 119:1256-62. 2006
    ....
  81. ncbi Australasian haematologist referral patterns to palliative care: lack of consensus on when and why
    K Auret
    School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
    Intern Med J 33:566-71. 2003
    ..Patients with haematological malignancies are not referred to palliative care services as frequently as those with solid cancers (non-haematological malignancies)...
  82. ncbi Nonmyeloablative stem cell transplantation with fludarabine and cyclophosphamide for patients with hematologic malignancies
    H Nakajima
    Division of Hematology Medical Oncology, Tokai University School of Medicine, Boseidai, Isehara, Japan
    Clin Lab Haematol 25:383-91. 2003
    ..A further study in large-scale setting is warranted...
  83. ncbi Outcomes of patients with haematological malignancies admitted to intensive care unit. A comparative review of allogeneic haematopoietic stem cell transplantation data
    ZiYi Lim
    Haematological Medicine, Kings College London and Kings College Hospital, London, UK
    Br J Haematol 136:448-50. 2007
    ..10%, P = 0.19). None of the nine myeloablative HSCT recipients survived (median survival: 9 d). Six of the 15 reduced-intensity conditioned HSCT recipients survived beyond 1 year (median survival: 1050 d, range: 438-1437)...
  84. ncbi Changes in severity and organ failure scores as prognostic factors in onco-hematological malignancy patients admitted to the ICU
    B Lamia
    Kremlin Bicetre University Hospital, Medical Intensive Care Department, 78 rue du General Leclerc, 94270 Le Kremlin Bicetre, France
    Intensive Care Med 32:1560-8. 2006
    ..To determine whether severity and organ failure scores over the first 3 days in an ICU predict in-hospital mortality in onco-hematological malignancy patients...
  85. ncbi Rapid helper T-cell recovery above 200 x 10 6/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation
    D H Kim
    Department of Hematology Oncology, Kyungpook National University Hospital, 50 Samduk 2 Ga, Jung Gu, Daegu 700 721, Korea
    Bone Marrow Transplant 37:1119-28. 2006
    ..In a multivariate analysis, rapid recovery of CD4+ helper T cells at 3 months was a favorable prognostic factor together with higher CD34+ cell transplant dose in terms of OS (P=0.001) and NRM (P=0.005)...
  86. ncbi Role of depression as a predictor of mortality among cancer patients after stem-cell transplantation
    Jesús M Prieto
    Department of Psychiatry, Clinical Institute of Psychiatry and Psychology, University of Barcelona, Spain
    J Clin Oncol 23:6063-71. 2005
    ..To determine the association between depression and survival among cancer patients at 1, 3, and 5 years after stem-cell transplantation (SCT)...
  87. ncbi Incidence and outcome of critical illness amongst hospitalised patients with haematological malignancy: a prospective observational study of ward and intensive care unit based care
    A C Gordon
    Department of Anaesthesia and Intensive Care, Barts and The London Queen Mary s School of Medicine and Dentistry, St Bartholomew s Hospital, West Smithfield, London, EC1A 7BE, UK
    Anaesthesia 60:340-7. 2005
    ..There was close agreement between actual and predicted mortality with increasing Simplified Acute Physiology Score II for all patients, including those not admitted to intensive care...
  88. ncbi Bone marrow transplantation in the course of hematological malignancies--follow-up study in blood serum by 31P MRS
    Małgorzata Kuliszkiewicz-Janus
    Department of Hematology, Wrocław University of Medicine, Poland
    Med Sci Monit 10:CR485-92. 2004
    ..Bone marrow transplantation (BMT) is one of the most efficient methods for the treatment of hematological neoplasms. Its successful application requires previous complete remission (CR) and exclusion of residual disease...
  89. ncbi Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors
    Jyotsna Reddy
    Hamon Center for Therapeutic Oncology Research, Dallas, TX 75390, USA
    Oncogene 24:732-6. 2005
    ....
  90. ncbi Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation
    J Vela-Ojeda
    Hematology Department, Stem Cell Transplant Program, Unidad Medica de Alta Especialidad Antonio Fraga Mouret National Medical Center La Raza, Instituto Mexicano del Seguro Social, Mexico, DF, Mexico
    Ann Hematol 85:113-20. 2006
    ..In conclusion, different circulating cell populations, other than CD34+ cells, are also of relevance in predicting the clinical outcome after allogeneic peripheral blood HSCT...
  91. ncbi Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
    Owen A O'Connor
    Department of Medicine, Division of Hematologic Oncology, Lymphoma Service, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, New York, NY 10021, USA
    J Clin Oncol 24:166-73. 2006
    ..To document the toxicity and activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with pretreated hematologic malignancies...
  92. ncbi A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease
    Xiao Jun Huang
    Peking University Institute of Hematology, People s Hospital, Beijing 100044, China
    Chin Med J (Engl) 117:1778-85. 2004
    ..We developed a new technique for HLA mismatched allogeneic HSCT using G-CSF primed bone marrow plus G-CSF-mobilized peripheral blood stem cells without ex vivo T cell depletion...
  93. ncbi Clinical implications of minimal residual disease monitoring for stem cell transplantation after reduced intensity and nonmyeloablative conditioning
    Avichai Shimoni
    Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Acta Haematol 112:93-104. 2004
    ..Immunotherapy is more effective for MRD than at frank relapse. Timing and dosing of therapy are not yet well established and depend on aggressiveness of the disease, type of conditioning, level and kinetics of MRD...
  94. ncbi A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation
    M J Hjermstad
    Department of Behavioural Sciences in Medicine, University of Oslo, Norway
    Bone Marrow Transplant 34:257-66. 2004
    ..This suggests a need for a closer follow-up of these patients with special emphasis on functional status and fatigue...
  95. ncbi Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors
    Razvan Diaconescu
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 104:1550-8. 2004
    ..In conclusion, nonmyeloablative regimens had lower RRT and NRM and could be considered for comparative studies, including younger patients with more favorable Charlson comorbidity scores...
  96. ncbi Recent developments in the management of invasive fungal infections in patients with hematological malignancies
    Meinolf Karthaus
    Medizinische Klinik II, Evangelisches Johannes Krankenhaus, Schildescher Strasse 99, 33611 Bielefeld, Germany
    Ann Hematol 84:207-16. 2005
    ..This review highlights recent developments in the epidemiology, diagnosis, and treatment in the context of state-of-the-art management of invasive fungal infections in cancer patients...
  97. ncbi Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation
    Daniel R Couriel
    Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4095, USA
    Biol Blood Marrow Transplant 10:178-85. 2004
    ..It is interesting to note that nonrelapse mortality with nonmyeloablative regimens in older and more debilitated patients was low (14%) and comparable to that achieved with standard high-dose regimens in younger patients...
  98. ncbi Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities
    Mohamed L Sorror
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109, USA
    Blood 104:961-8. 2004
    ..After adjustment for pretransplantation differences between the 2 patient groups, the hazard ratio was 3.0 (P=.04). Multivariate analyses showed higher pretransplantation comorbidity scores to result in increased toxicity and mortality...
  99. ncbi Role of epigenetic changes in hematological malignancies
    Ulrich Lehmann
    Institute of Pathology, Medizinische Hochschule Hannover, Carl Neuberg Str 1, 30625, Hannover, Germany
    Ann Hematol 83:137-52. 2004
    ..In addition, the implications for therapy and prognosis will be discussed...
  100. ncbi Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies
    D Valcarcel
    Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
    Eur J Haematol 74:144-51. 2005
    ..Nevertheless, high mortality rates may be associated with this therapy, especially in older patients, those with other comorbidities or who receive a second HSCT...
  101. ncbi Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA-identical and mismatched transplants
    Andrew Daly
    Allogeneic Bone Marrow Transplant Program, Princess Margaret Hospital University Health Network, University of Toronto, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    Biol Blood Marrow Transplant 9:373-82. 2003
    ..We conclude that a quantitative T-cell deficiency in these extensively T-cell depleted patients may be a risk factor for infection, even in the absence of graft-versus-host disease...

Research Grants106 found, 100 shown here

  1. Duke Comp Cancer Inst. Core Support Grant
    HERBERT KIM LYERLY; Fiscal Year: 2010
    ..A cancer focus is illustrated by $2,991,535 or 11.3% of funding from the NCI, the American Cancer Society or the Department of Defense. ..
  2. GENETIC ANALYSIS OF POLARITY
    RUTH M STEWARD; Fiscal Year: 2010
    ..We are aiming at developing a PCR approach to differentiate between the forms of PDCD2 found in normal bone marrow and blood, and the PDCD2 forms associated with leukemic cells. ..
  3. GENETIC ANALYSIS OF POLARITY
    Ruth Steward; Fiscal Year: 2009
    ..We are aiming at developing a PCR approach to differentiate between the forms of PDCD2 found in normal bone marrow and blood, and the PDCD2 forms associated with leukemic cells. ..
  4. Targeting aberrant epigenetics by nanomedicine
    Shujun Liu; Fiscal Year: 2010
    ....
  5. HEMATOPOIETIC STEM CELLS FOR TRANSPLANTATION
    Curt Civin; Fiscal Year: 2005
    ..M1A. INCLUSION OF CHILDREN PLAN (Resume): Acceptable. Patients of all ages can be included in these studies. C1A. VERTEBRATE ANIMALS (Resume): None. PROJECT 2: Pathophysiology of PNH (Robert Brodsky, M.D.) ..
  6. Bone Marrow Transplantation for Hematologic Malignancies using Novel Radioimmunot
    John M Pagel; Fiscal Year: 2010
    ..We anticipate that these approaches will cure more patients and cause fewer toxicities than currently available therapies. ..
  7. University of New Mexico Cancer Center Support
    Cheryl L Willman; Fiscal Year: 2010
    ..It is focused on the delivery of outstanding care to the peoples of the region and overcoming their cancer health disparities through community programs and partnerships. ..
  8. System for Rapid Generation of Aptamers for Transplant Therapies
    KAREN QIAN; Fiscal Year: 2010
    ....
  9. Post-transplant vaccines to enhance graft-versus-leukemia responses
    CATHERINE JU YING WU; Fiscal Year: 2010
    ..End of Abstract) ..
  10. Training Patients and Partners for HSCT: A Novel Coping Skills Intervention
    Catalina Lawsin; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  11. CORE--RADIOIMMUNOTHERAPY
    Andrew Raubitschek; Fiscal Year: 2000
    ..This novel method should afford more efficacious treatment will also assist in the development of the INDs covering the anti-CD33 and anti-CD20 monoclonal antibodies and their associated radioimmunoconjugates. ..
  12. AUTOMATED CLOSED SYSTEM FOR DMSO REMOVAL FROM PERIPHERAL BLOOD STEM CELLS
    ERIK WOODS; Fiscal Year: 2007
    ..The goal of this research is to produce a device to easily remove DMSO from PBSC before they are transplanted, increasing effectiveness of the cells and reducing potential complications. [unreadable] [unreadable] [unreadable]..
  13. Enhancing neutrophil function in neutropenia-related pneumonia
    Hongbo Luo; Fiscal Year: 2009
    ..In addition, although we focus on neutropenia-related pneumonia in this application, the same strategy can be readily applied to other neutropenia-related infectious diseases. ..
  14. Enhancing neutrophil function in neutropenia-related pneumonia
    Hongbo R Luo; Fiscal Year: 2010
    ..In addition, although we focus on neutropenia-related pneumonia in this application, the same strategy can be readily applied to other neutropenia-related infectious diseases. ..
  15. Role of JAK2V617F in the Pathogenesis of Myeloproliferative Disorders.
    M Golam Mohi; Fiscal Year: 2009
    ..The results of these studies may identify new therapeutic targets for MPDs. Moreover, our inducible JAK2V617F knock-in mouse will provide a unique and reproducible animal model to test novel therapies for JAK2V617F-associated MPDs. ..
  16. Role of JAK2V617F in the Pathogenesis of Myeloproliferative Disorders.
    M Golam Mohi; Fiscal Year: 2009
    ..The results of these studies may identify new therapeutic targets for MPDs. Moreover, our inducible JAK2V617F knock-in mouse will provide a unique and reproducible animal model to test novel therapies for JAK2V617F-associated MPDs. ..
  17. Histone Deacetylase Inhibition: A Novel Approach to Cardioprotection
    Ting Zhao; Fiscal Year: 2009
    ....
  18. Histone Deacetylase Inhibition: A Novel Approach to Cardioprotection
    Ting C Zhao; Fiscal Year: 2010
    ....
  19. Genome Wide Admixture Scan for Multiple Myeloma in African Americans
    CHRISTOPHER ALAN HAIMAN; Fiscal Year: 2010
    ..Our ultimate goal is to reduce the health disparity experienced by African Americans due to this fatal cancer. ..
  20. Novel therapies for Fanconi anemia
    DAVID A contact WILLIAMS; Fiscal Year: 2010
    ....
  21. Substrata Interactions of Normal and Leukemic Hematopoietic Stem Cells
    Jane Liesveld; Fiscal Year: 2009
    ..They also have implication for understanding of survival and proliferation of normal stem cells which would have impact on stem cell transplantation and implantation therapies. ..
  22. Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer
    Paul J Shami; Fiscal Year: 2012
    ..This new drug then goes one step further: it will improve the quality of life for cancer patients, their caregivers and families by providing a significantly more effective and less painful therapy than is currently available. ..
  23. Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer
    Paul J Shami; Fiscal Year: 2010
    ..This new drug then goes one step further: it will improve the quality of life for cancer patients, their caregivers and families by providing a significantly more effective and less painful therapy than is currently available. ..
  24. THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES
    Oliver Press; Fiscal Year: 2006
    ..We anticipate that these investigations will allow us to maximize the therapeutic efficacy and minimize the toxicity of myeloablative RIT for hematologic malignancies. ..
  25. THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES
    Oliver Press; Fiscal Year: 2009
    ..We anticipate that these investigations will allow us to maximize the therapeutic efficacy and minimize the toxicity of myeloablative RIT for hematologic malignancies. ..
  26. The Molecular Pathology of Myeloproliferative Disease
    Jonathan Licht; Fiscal Year: 2006
    ..abstract_text> ..
  27. The Molecular Pathology of Myeloproliferative Disease
    Jonathan Licht; Fiscal Year: 2006
    ..abstract_text> ..
  28. The Molecular Pathology of Myeloproliferative Disease
    Jonathan Licht; Fiscal Year: 2005
    ..abstract_text> ..
  29. The Molecular Pathology of Myeloproliferative Disease
    Jonathan Licht; Fiscal Year: 2007
    ..abstract_text> ..
  30. A novel method for identification of minor histocompatibility antigens
    Brad Stone; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  31. Minor Histocompatilibity Vaccination After Allo-Transpl*
    Koen Van Besien; Fiscal Year: 2003
    ..Blood, marrow and skin biopsy samples will be obtained for correlative studies relating to immune reconstitution and minimal residual disease and compared with historical controls. ..
  32. Minor Histocompatilibity Vaccination After Allo-Transpl*
    Koen Van Besien; Fiscal Year: 2004
    ..Blood, marrow and skin biopsy samples will be obtained for correlative studies relating to immune reconstitution and minimal residual disease and compared with historical controls. ..
  33. There Will Be Blood: Stem Cell Niche Driven Derivation of HSC from ES Cells
    PAUL JOHN SIMMONS; Fiscal Year: 2010
    ..This proposal seeks to develop markedly improved strategies to derive HSC from pluripotent stem cells as a means to overcome this limitation and to further the development of novel cellular therapies for treating blood diseases. ..
  34. GENE DEFECTS OF BAND 11Q23 IN HEMATOLOGIC MALIGNANCIES
    JORGE YUNIS; Fiscal Year: 1990
    ....
  35. IMMUNOREGULATORY EFFECTS OF THE INTERFERONS
    Howard Ozer; Fiscal Year: 1990
    ..They have demonstrated significant clinical activity in hematologic neoplasms and our own data imply a direct, antiproliferative mechanism of action mediated via specific cell surface ..
  36. CANCER IMMUNOTHERAPEUTICS PROGRAM
    Andrew Raubitschek; Fiscal Year: 2003
    ..since the last competitive grant review. Of these, 51 are intraprogrammatic publications, 12 are interprogrammatic publications, and 11 are both. ..
  37. THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES
    Oliver Press; Fiscal Year: 2007
    ..We anticipate that these investigations will allow us to maximize the therapeutic efficacy and minimize the toxicity of myeloablative RIT for hematologic malignancies. ..
  38. THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES
    Oliver Press; Fiscal Year: 2005
    ..We anticipate that these investigations will allow us to maximize the therapeutic efficacy and minimize the toxicity of myeloablative RIT for hematologic malignancies. ..
  39. IL-15 Superagonist Complex as an Immunotherapeutic for Multiple Myeloma
    Hing C Wong; Fiscal Year: 2012
    ..Positive outcomes from this proposed study would provide justification for clinical development of this complex as a safe, durable, potent and cell-mediated immunotherapy to treat patients with multiple myeloma. ..
  40. The Role of hPso4 in DNA Repair and Chemotherapy Resistance
    Montaser Shaheen; Fiscal Year: 2010
    ..Our project aims to characterize the precise role of the DNA repair protein human Pso4 in this process and to investigate its mechanism of action and its potential role in chemotherapy resistance. (End of Abstract) ..
  41. NUCLEOSIDE AND NUCLEOTIDE METABOLIZING ENZYMES
    Beverly Mitchell; Fiscal Year: 1999
    ....
  42. Inosine Monophosphate Dehydrogenase: Regulation and Function
    Beverly Mitchell; Fiscal Year: 2007
    ..abstract_text> ..
  43. REGULATION OF HLA CLASS I GENE EXPRESSION IN HUMAN TUMOR
    GORDON GINDER; Fiscal Year: 1993
    ....
  44. Inosine Monophosphate Dehydrogenase: Regulation and Function
    Beverly Mitchell; Fiscal Year: 2005
    ..abstract_text> ..
  45. Inosine Monophosphate Dehydrogenase: Regulation and Function
    Beverly Mitchell; Fiscal Year: 2006
    ..abstract_text> ..
  46. Inosine Monophosphate Dehydrogenase: Regulation/Function
    Beverly Mitchell; Fiscal Year: 2003
    ..abstract_text> ..
  47. Inosine Monophosphate Dehydrogenase: Regulation and Function
    Beverly Mitchell; Fiscal Year: 2004
    ..abstract_text> ..
  48. Targeting PML for therapy in leukemia-initiating cells
    Keisuke Ito; Fiscal Year: 2010
    ..The elucidation of the mechanisms by which PML regulates the maintenance of the LIC pool could in turn lead to novel therapeutic approaches to treat leukemia. ..
  49. Twenty-second Annual Fanconi Anemia Research Fund Scientific Symposium
    GROVER CARLTON BAGBY; Fiscal Year: 2010
    ..Its relatively small scale and concentrated focus promotes interaction and collaboration between participants across the globe. The meeting provides an excellent training environment for junior investigators and trainees. ..
  50. Transcriptional Functions and Targets of the MMSET Protein of t(4:14) Myeloma
    Jonathan Licht; Fiscal Year: 2009
    ..These data lead to our overarching hypothesis that aberrant overexpression of MMSET leads to deregulated gene expression in B cells, contributing to the pathogenesis of myeloma. ..
  51. Transcriptional Functions and Targets of the MMSET Protein of t(4:14) Myeloma
    Jonathan D Licht; Fiscal Year: 2010
    ..These data lead to our overarching hypothesis that aberrant overexpression of MMSET leads to deregulated gene expression in B cells, contributing to the pathogenesis of myeloma. ..
  52. Phase I/II Study of MS-275 and 5-Azacytidine in Patients with Advanced Non-Small
    CHARLES RUDIN; Fiscal Year: 2007
    ..If successful, this approach could alter the poor prognosis of individuals with this disease. [unreadable] [unreadable] [unreadable]..
  53. TYROSINE KINASE FUSION IN HEMATOLOGIC MALIGNANCY
    D Gilliland; Fiscal Year: 1999
    ..Furthermore, these studies will provide a foundation for immunotherapeutic approaches to leukemia and lymphoma. ..
  54. TYROSINE KINASE FUSION IN HEMATOLOGIC MALIGNANCY
    D Gilliland; Fiscal Year: 2001
    ..Furthermore, these studies will provide a foundation for immunotherapeutic approaches to leukemia and lymphoma. ..
  55. ADHESION MOLECULES MEDIATING SKIN TROPISM IN ACUTE GVHD
    Robert Sackstein; Fiscal Year: 2003
    ....
  56. ADHESION MOLECULES MEDIATING SKIN TROPISM IN ACUTE GVHD
    Robert Sackstein; Fiscal Year: 2002
    ....
  57. ADHESION MOLECULES MEDIATING SKIN TROPISM IN ACUTE GVHD
    Robert Sackstein; Fiscal Year: 2001
    ....
  58. TYROSINE KINASE FUSION IN HEMATOLOGIC MALIGNANCY
    D Gilliland; Fiscal Year: 2000
    ..Furthermore, these studies will provide a foundation for immunotherapeutic approaches to leukemia and lymphoma. ..
  59. ADHESION MOLECULES MEDIATING SKIN TROPISM IN ACUTE GVHD
    Robert Sackstein; Fiscal Year: 2000
    ....
  60. Leukemia Stem Cells: Essential Targets for GVL and Mediators of GVL-Resistance
    Warren Shlomchik; Fiscal Year: 2009
    ..Unfortunately, for reasons that are unknown, many cancers are resistant to this therapy and this proposal will investigate the biology underlying this differential sensitivity. ..
  61. CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCY
    John Levine; Fiscal Year: 2002
    ..2A. To evaluate a panel of cytokines as surrogate markers for GVHD and correlate these with clinical outcomes during the above trial. 2B. To correlate changes in minimal residual disease with clinical outcomes during the above trial. ..
  62. Leukemia Stem Cells: Essential Targets for GVL and Mediators of GVL-Resistance
    Warren D Shlomchik; Fiscal Year: 2010
    ..Unfortunately, for reasons that are unknown, many cancers are resistant to this therapy and this proposal will investigate the biology underlying this differential sensitivity. ..
  63. CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCY
    John Levine; Fiscal Year: 2003
    ..2A. To evaluate a panel of cytokines as surrogate markers for GVHD and correlate these with clinical outcomes during the above trial. 2B. To correlate changes in minimal residual disease with clinical outcomes during the above trial. ..
  64. RADIOIMMUNOTHERAPY AND BONE MARROW TRANSPLANTATION IN HEMATOLOGIC MALIGNANCY
    Andrew Raubitschek; Fiscal Year: 1999
    ..Further modification of this DOTA chelate will be evaluated as potential reagents for clinical utility in the treatment of the leukemias and lymphomas covered under this study. ..
  65. CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCY
    John Levine; Fiscal Year: 2004
    ..2A. To evaluate a panel of cytokines as surrogate markers for GVHD and correlate these with clinical outcomes during the above trial. 2B. To correlate changes in minimal residual disease with clinical outcomes during the above trial. ..
  66. GENE THERAPY OF HEMATOLOGIC MALIGNANCIES
    KAMEHAMEHA WONG; Fiscal Year: 1999
    ....
  67. CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCY
    John Levine; Fiscal Year: 2005
    ..2A. To evaluate a panel of cytokines as surrogate markers for GVHD and correlate these with clinical outcomes during the above trial. 2B. To correlate changes in minimal residual disease with clinical outcomes during the above trial. ..
  68. Phase I study of 8-Cl-adenosine in CLL (IND 68,229)
    Varsha Gandhi; Fiscal Year: 2009
    ..The investigators state that these Aims will establish utility of 8-Cl-Ado in CLL, provide a dose for Phase 2 study, and knowledge for optimal use of this agent alone and in combination. ..
  69. CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCY
    John Levine; Fiscal Year: 2001
    ..2A. To evaluate a panel of cytokines as surrogate markers for GVHD and correlate these with clinical outcomes during the above trial. 2B. To correlate changes in minimal residual disease with clinical outcomes during the above trial. ..
  70. CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCY
    John Levine; Fiscal Year: 2006
    ..2A. To evaluate a panel of cytokines as surrogate markers for GVHD and correlate these with clinical outcomes during the above trial. 2B. To correlate changes in minimal residual disease with clinical outcomes during the above trial. ..
  71. 24th Annual Fanconi Anemia Research Fund Scientific Symposium
    GROVER CARLTON BAGBY; Fiscal Year: 2012
    ..Acquired abnormalities of FA genes and FA gene expression have been reported in patients with sporadic malignancies of plasma cells, leukemia, head and neck cancer, lung cancer, and ovarian cancer. ..
  72. CANCER AND LEUKEMIA GROUP B--MINNESOTA ONCOLOGY GROUP
    Bruce Peterson; Fiscal Year: 1993
    ..The objective of this research program is to participate in inter-institutional clinical research to resolve unanswered and important questions in the therapy and biology of malignant diseases...
  73. Targeting aberrant epigenetics by nanomedicine
    Shujun Liu; Fiscal Year: 2012
    ..abstract_text> ..
  74. 2012 CRTI Summer Workshop
    Mark Crowther; Fiscal Year: 2012
    ....
  75. Blood vs. bone marrow stem transplant
    Benjamin Djulbegovic; Fiscal Year: 2002
    ..We will test all these hypotheses by collecting individual-patient data on each outcomes of interest from the existing data sets (i.e. from published and unpublished randomized studies) using the techniques of SR/MA. ..
  76. Blood vs. bone marrow stem transplant
    Benjamin Djulbegovic; Fiscal Year: 2003
    ..We will test all these hypotheses by collecting individual-patient data on each outcomes of interest from the existing data sets (i.e. from published and unpublished randomized studies) using the techniques of SR/MA. ..
  77. ROLE OF THE G-CSF RECEPTOR IN PROGENITOR MOBILIZATION
    Daniel C Link; Fiscal Year: 2011
    ..We believe this research will lead to novel strategies to mobilized blood stem cells for transplantation, enhance engraftment of stem cells after transplantation, and potential treat leukemia. ..
  78. Genetic Manipulation of T Cells--PreClinical Models
    John Dipersio; Fiscal Year: 2001
    ..Issues regarding the use of genetically manipulated T-cells to control GvHD can best be investigated through the use of informative animal models and the comprehensive studies described in this proposal. ..
  79. Genetic Manipulation of T Cells--PreClinical Models
    John Dipersio; Fiscal Year: 2002
    ..Issues regarding the use of genetically manipulated T-cells to control GvHD can best be investigated through the use of informative animal models and the comprehensive studies described in this proposal. ..
  80. Genetic Manipulation of T Cells--PreClinical Models
    John Dipersio; Fiscal Year: 2003
    ..Issues regarding the use of genetically manipulated T-cells to control GvHD can best be investigated through the use of informative animal models and the comprehensive studies described in this proposal. ..
  81. Genetic Manipulation of T Cells--PreClinical Models
    John Dipersio; Fiscal Year: 2005
    ..Issues regarding the use of genetically manipulated T-cells to control GvHD can best be investigated through the use of informative animal models and the comprehensive studies described in this proposal. ..
  82. Genetic Manipulation of T Cells--PreClinical Models
    John Dipersio; Fiscal Year: 2004
    ..Issues regarding the use of genetically manipulated T-cells to control GvHD can best be investigated through the use of informative animal models and the comprehensive studies described in this proposal. ..
  83. NOVEL SEROTHERAPY STRATEGIES--PLASMA CELL MALIGNANCIES
    STEVEN TREON; Fiscal Year: 2003
    ..Analogous to our work with Muc-1, we will also attempt to identify other PCD selective targets by generating and examining mAbs specific to the plasma cell glycoform of CD138. ..
  84. NOVEL SEROTHERAPY STRATEGIES--PLASMA CELL MALIGNANCIES
    STEVEN TREON; Fiscal Year: 2001
    ..Analogous to our work with Muc-1, we will also attempt to identify other PCD selective targets by generating and examining mAbs specific to the plasma cell glycoform of CD138. ..
  85. Genetic Variation in Vitamin D Metabolism and BMT Outcomes
    KIMBERLY ROBIEN; Fiscal Year: 2009
    ....
  86. High Performance Magnetic Cell Sorting
    JEFFREY CHALMERS; Fiscal Year: 2006
    ..abstract_text> ..
  87. High Performance Magnetic Cell Sorting
    JEFFREY CHALMERS; Fiscal Year: 2005
    ..abstract_text> ..
  88. DLI using genetically modified T cells: Phase 1 trial
    John Dipersio; Fiscal Year: 2004
    ..abstract_text> ..
  89. Stable shRNA-mediated gene silencing of the beta 7 integrin to ameliorate graft-v
    Jenny Zilberberg; Fiscal Year: 2010
    ....
  90. High Performance Magnetic Cell Sorting
    JEFFREY CHALMERS; Fiscal Year: 2004
    ..abstract_text> ..
  91. High Performance Magnetic Cell Sorting
    JEFFREY CHALMERS; Fiscal Year: 2003
    ..abstract_text> ..
  92. DLI using genetically modified T cells: Phase 1 trial
    John Dipersio; Fiscal Year: 2005
    ..abstract_text> ..
  93. Hematopoietic Cell Transplantation for Hematologic Malignancies
    Stephen J Forman; Fiscal Year: 2010
    ....
  94. Hematopoietic Cell Transplantation for Hematologic Malignancies
    Stephen J Forman; Fiscal Year: 2010
    ..abstract_text> ..
  95. Hematopoietic Cell Transplantation for Hematologic Malignancies
    STEPHEN FORMA; Fiscal Year: 2007
    ....